BRAF p.V600E

About

Biomarker type: Somatic variant

Gene context: BRAF

HGVS.p: NP_004324.2:p.Val600Glu

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) BRAF p.V600E Melanoma Atezolizumab, Cobimetinib, Vemurafenib
FDA (4) HC (2) BRAF p.V600E Melanoma Binimetinib, Encorafenib
FDA (4) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib
FDA (4) HC (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
FDA (2) HC (1) BRAF p.V600E Melanoma Cobimetinib, Vemurafenib
FDA (2) HC (1) BRAF p.V600E Melanoma Dabrafenib
FDA (8) BRAF p.V600E Melanoma Dabrafenib, Trametinib
FDA (4) HC (2) BRAF p.V600E Non-Small Cell Lung Cancer Dabrafenib, Trametinib
FDA (4) BRAF p.V600E Anaplastic Thyroid Cancer Dabrafenib, Trametinib
FDA (4) BRAF p.V600E Any solid tumor Dabrafenib, Trametinib
FDA (4) HC (2) BRAF p.V600E Low-Grade Glioma Dabrafenib, Trametinib
FDA (2) HC (1) BRAF p.V600E Melanoma Trametinib
FDA (2) HC (1) BRAF p.V600E Melanoma Vemurafenib
FDA (2) BRAF p.V600E Erdheim-Chester Disease Vemurafenib
FDA (2) BRAF p.V600E Low-Grade Glioma Tovorafenib
FDA (2) HC (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
HC (2) BRAF p.V600E High-Grade Glioma Dabrafenib, Trametinib
HC (1) BRAF p.V600E Melanoma Pembrolizumab
HC (1) BRAF p.V600E Melanoma Nivolumab
FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Irinotecan